Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.
about
Diet and Alzheimer’s disease risk factors or prevention: the current evidenceBiological markers of amyloid beta-related mechanisms in Alzheimer's diseaseThe clinical problem of symptomatic Alzheimer disease and mild cognitive impairmentThe Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionCerebrospinal fluid and blood biomarkers in Alzheimer's diseaseDementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review.The role of biomarkers in clinical trials for Alzheimer diseaseThe Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.Biomarker identification in neurologic diseases: improving diagnostics and therapeutics.Total and phosphorylated tau protein as biological markers of Alzheimer's disease.Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of diseaseAlzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.Diagnosis and biomarkers of predementia in Alzheimer's disease.Olfactory impairment in presymptomatic Alzheimer's disease.Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scansBiological markers and Alzheimer disease: a canadian perspectiveQualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometryStructural MRI biomarkers for preclinical and mild Alzheimer's disease.A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Mediterranean diet, Alzheimer disease, and vascular mediationDivergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsySerum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.The application of functional genomics to Alzheimer's disease.Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.CSF tau and β-amyloid as biomarkers for mild cognitive impairment.Biological markers for early detection and pharmacological treatment of Alzheimer's disease.Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.Using biomarkers to improve detection of Alzheimer's disease.Looking backward to move forward: early detection of neurodegenerative disorders.Association of C-reactive protein with cognitive impairment.Diagnostic Utility of CSF Tau and Aβ(42) in Dementia: A Meta-Analysis.Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsVariations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level.
P2860
Q22241476-6A403CEE-ECF7-4A90-966F-544BBD0F0724Q24622136-EABA3FF4-D1AC-4733-966A-D81F0D2B65F2Q26849795-BBFC4D44-8E5F-4E08-80D5-8DB48D443156Q27006831-B6E20182-6D9E-437B-A848-F6A8F66BAAD9Q27023758-AA1F809E-2E83-4591-873E-D5D71ED566E1Q28943531-C1E6C841-8F6F-4805-995D-F050379F99C9Q30971403-E4EB4C6D-D6DC-43AB-9B8F-C2F4C6C36A71Q31020589-C93CB8F3-6C87-47DF-BE2C-CB8EE6A04F0AQ31032781-566B3967-F35C-4B41-9CB9-230895D82CFEQ31048037-A4E2857C-77F5-4271-A65E-36E807C7B44CQ33202814-1CEC96EA-F699-46A9-B4FD-EC7BF67F561BQ33624674-74192EC7-7373-4C45-B632-8CC803A50B51Q33736357-D3272B65-88BB-4F8B-95D3-156AEE8D4C17Q33736582-35F1A9CB-A5D0-419D-9F79-3777D0D00561Q33759240-AC5C2152-1C5E-419F-A895-06101D90B727Q33777509-AA83C468-B919-460B-821E-9D4C819E2FC6Q33802937-B54FA7FA-C9A3-4EC8-8C44-A8B0BBDDC8CFQ33924646-62BB5276-647A-40A6-B6E8-BEEA0BB3C474Q34065449-BE8A657B-388A-4294-9428-FA21C841AEB3Q34081087-DD9CAEC6-F3F7-4149-90D0-CAFC08B863CEQ34089784-91018BB9-6351-4B35-84B9-5DA0298A286AQ34157882-A73B2F57-D309-44D4-9CC0-65A5D49B42CAQ34180987-B890F642-958E-4B8F-A142-F139598291AFQ34341870-53FFA6E9-E6D4-4F8C-AB0E-7BAE04B4CAD4Q34510165-76DB9EAC-E71F-499F-B3E4-1B35B769931AQ34633220-75C7D6BB-40C7-473E-ADCB-0C71ED02CC5EQ34648414-E47C9B94-634E-4AA2-B92C-4754AF250B38Q35029086-3F830200-570E-4EB8-AA2D-D1CEBD5E7162Q35166684-4F226A79-FD7E-4734-984D-DF14586F7B45Q35207554-A99836A8-352A-4E80-9F90-97C4BEE63FFDQ35218413-8E9A2C14-F93A-4A11-8E3D-308DDACC81D1Q35236838-410D3BB2-AA84-46C3-8E1C-B31ABAF24DC1Q35237100-9DC78982-C4A1-481E-9367-71C2F6B74E0CQ35483725-2D7934E4-EE3D-4DC2-BF5F-17B22F55993DQ35533115-505ABB12-C2FE-465B-BAD8-873837FF9711Q35573431-F3B54452-FBE6-4033-BAAE-91509C97EAE2Q35591752-E00817B2-2640-4A14-A757-04438447803CQ35606785-EE83C342-94B0-4C8D-AB0D-D0DE03DC79B1Q35649302-57064FF7-0AEA-4C40-AAFB-D62EF4C0052FQ35740031-DCAF5AE7-96BB-41A2-B7E8-6242E3BAA79A
P2860
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Biological markers for therape ...... maging in Alzheimer's disease.
@ast
Biological markers for therape ...... maging in Alzheimer's disease.
@en
type
label
Biological markers for therape ...... maging in Alzheimer's disease.
@ast
Biological markers for therape ...... maging in Alzheimer's disease.
@en
prefLabel
Biological markers for therape ...... maging in Alzheimer's disease.
@ast
Biological markers for therape ...... maging in Alzheimer's disease.
@en
P2093
P50
P921
P1476
Biological markers for therape ...... maging in Alzheimer's disease.
@en
P2093
Douglas Galasko
Eric Siemers
Joseph Rogers
Mony J de Leon
National Institute on Aging Biological Markers Working Group
Pankaj D Mehta
Richard A Frank
P304
P356
10.1016/S0197-4580(03)00002-2
P577
2003-07-01T00:00:00Z